» Articles » PMID: 38164594

Fanning the Flames of Endoplasmic Reticulum (ER) Stress: Can Sphingolipid Metabolism Be Targeted to Enhance ER Stress-Associated Immunogenic Cell Death in Cancer?

Overview
Journal Mol Pharmacol
Date 2024 Jan 2
PMID 38164594
Authors
Affiliations
Soon will be listed here.
Abstract

The three arms of the unfolded protein response (UPR) surveil the luminal environment of the endoplasmic reticulum (ER) and transmit information through the lipid bilayer to the cytoplasm to alert the cell of stress conditions within the ER lumen. That same lipid bilayer is the site of de novo synthesis of phospholipids and sphingolipids. Thus, it is no surprise that lipids are modulated by and are modulators of ER stress. Given that sphingolipids have both prosurvival and proapoptotic effects, they also exert opposing effects on life/death decisions in the face of prolonged ER stress detected by the UPR. In this review, we will focus on several recent studies that demonstrate how sphingolipids affect each arm of the UPR. We will also discuss the role of sphingolipids in the process of immunogenic cell death downstream of the protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiating factor 2 (eIF2) arm of the UPR. Furthermore, we will discuss strategies to target the sphingolipid metabolic pathway that could potentially act synergistically with agents that induce ER stress as novel anticancer treatments. SIGNIFICANCE STATEMENT: This review provides the readers with a brief discussion of the sphingolipid metabolic pathway and the unfolded protein response. The primary focus of the review is the mechanism(s) by which sphingolipids modulate the endoplasmic reticulum (ER) stress response pathways and the critical role of sphingolipids in the process of immunogenic cell death associated with the ER stress response.

Citing Articles

Synergistic effect of the sphingosine kinase inhibitor safingol in combination with 2'-nitroflavone in breast cancer.

Anselmi Relats J, Roguin L, Marder M, Cercato M, Marino J, Blank V J Mol Med (Berl). 2024; 102(12):1503-1516.

PMID: 39503902 DOI: 10.1007/s00109-024-02497-7.

References
1.
Turubanova V, Balalaeva I, Mishchenko T, Catanzaro E, Alzeibak R, Peskova N . Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019; 7(1):350. PMC: 6916435. DOI: 10.1186/s40425-019-0826-3. View

2.
Siow D, Sunkara M, Morris A, Wattenberg B . Regulation of de novo sphingolipid biosynthesis by the ORMDL proteins and sphingosine kinase-1. Adv Biol Regul. 2014; 57:42-54. DOI: 10.1016/j.jbior.2014.09.002. View

3.
Spisek R, Charalambous A, Mazumder A, Vesole D, Jagannath S, Dhodapkar M . Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007; 109(11):4839-45. PMC: 1885516. DOI: 10.1182/blood-2006-10-054221. View

4.
Pitson S, Moretti P, Zebol J, Lynn H, Xia P, Vadas M . Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003; 22(20):5491-500. PMC: 213794. DOI: 10.1093/emboj/cdg540. View

5.
French K, Upson J, Keller S, Zhuang Y, Yun J, Smith C . Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006; 318(2):596-603. DOI: 10.1124/jpet.106.101345. View